Sargent Bickham Lagudis’s Genmab GMAB Stock Holding History

Sargent Bickham Lagudis’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-46	Closed	-$1K	–	1043
2022 Q2	$1K	Buy	+46	New	+$1.49K	﹤0.01%	985

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sargent Bickham Lagudis's GMAB Position: Q3 2022 in Review

Sargent Bickham Lagudis sold out of Genmab (GMAB) in Q3 2022, closing a stake of 46 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in GMAB in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 193 funds tracked by Wall St. Rank hold GMAB as of Q3 2022.

Sargent Bickham Lagudis reported no remaining Genmab position as of Q3 2022 after selling out during the quarter.
Sargent Bickham Lagudis sold 46 Genmab shares in Q3 2022, an estimated $1K.
Sargent Bickham Lagudis first reported a position in Genmab in Q2 2022 and held it in 1 quarter.
Sargent Bickham Lagudis's Genmab position peaked at $1K in Q2 2022.
193 funds tracked by Wall St. Rank held Genmab as of Q3 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q3 2022, filed 27 Oct 2022.